Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Thromb Haemost. 2013 Mar;11(3):539-46. doi: 10.1111/jth.12128.

Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain.

Author information

  • 1Inserm, Inserm UMR-S U919, University of Caen Basse-Normandie, Serine Proteases and Pathophysiology of Neurovascular Unit, GIP Cyceron, Caen, France.

Abstract

BACKGROUND:

Thrombolysis with tissue-type plasminogen activator (t-PA) is the only treatment approved for acute ischemic stroke. Although t-PA is an efficient clot lysis enzyme, it also causes damage to the neurovascular unit, including hemorrhagic transformations and neurotoxicity.

OBJECTIVES:

On the basis of the mechanism of action of t-PA on neurotoxicity, we aimed at studying the molecular requirements to generate safer thrombolytics.

METHODS:

We produced original t-PA-related mutants, including a non-cleavable single-chain form with restored zymogenicity (sc*-t-PA) and a t-PA modified in the kringle 2 lysine-binding site (K2*-t-PA). Both sc*-t-PA and K2*-t-PA showed fibrinolytic activities similar to that of wild-type t-PA on both euglobulin-containing and plasma-containing clots. In contrast to wild-type t-PA, the two mutants did not promote N-methyl-d-aspartate receptor-mediated neurotoxicity.

CONCLUSIONS:

We designed t-PA mutants with molecular properties that, in contrast to t-PA, do not induce neurotoxicity.

© 2013 International Society on Thrombosis and Haemostasis.

PMID:
23301636
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk